GHK-Cu: Collagen, Copper, and the Limits of a Tiny Peptide

The short version

GHK-Cu is a three-amino-acid peptide — glycine, histidine, lysine — held in a one-to-one grip with a single copper(II) ion. You will also see it called copper tripeptide-1. That GHK sequence exists naturally inside type I collagen, the main structural scaffold of skin and tendon, which is the first clue to what the complex does: it signals the cells that build skin's scaffolding to make more of it ^[4].

The best-evidenced use is topical. Multiple small trials report that applying GHK-Cu to skin increases collagen production and measurably improves signs of aging compared with vitamin C and retinoic acid controls ^[1][4]. A 6-month RCT of a GHK-containing formulation in 45 men with male-pattern hair loss showed statistically significant hair-count gains over placebo ^[3]. The honest counterweight: the peptide crosses intact skin poorly ^[1], almost all mechanistic evidence is in cell cultures or small trials, and injectable or systemic use of GHK-Cu has no approved indication and no validated human pharmacokinetics. This page summarizes the studies; it is not advice and lists no human dose.

What it is

GHK-Cu is the copper(II) chelate of the linear tripeptide glycyl-L-histidyl-L-lysine. The copper ion is coordinated through the histidine imidazole nitrogen, the glycine alpha-amino nitrogen, and the deprotonated glycine-histidine amide nitrogen, leaving the lysine side chain free. Molecular formula C14H23CuN6O4+ — a small cationic complex with a molecular weight around 402.9 Da and CAS number 89030-95-5.

The bare GHK sequence occurs endogenously within the alpha-2(I) chain of type I collagen and in the matrix protein SPARC/osteonectin. Plasma GHK is measurable in humans — approximately 200 ng/mL at age 20 — and declines to around 80 ng/mL by age 60, a fact the skin-aging literature uses to motivate topical replacement strategies ^[4]. Copper coordination is required for most of the reported bioactivities; the free tripeptide (GHK) and its copper chelate (GHK-Cu) are functionally distinct, though they are frequently conflated in secondary sources.

How it works

GHK-Cu plays two roles simultaneously. As a copper chaperone it delivers copper into the extracellular environment where lysyl oxidase uses it to cross-link newly synthesized collagen and elastin, giving those fibers mechanical strength. As a signaling molecule it acts at picomolar-to-nanomolar concentrations to tell dermal fibroblasts to ramp up production of collagen, elastin, glycosaminoglycans, and the structural proteoglycan decorin, while rebalancing the matrix metalloproteinases that degrade matrix against their TIMP inhibitors ^[4][6].

The tissue-remodeling scope is wider than the skin. A 2008 review catalogued GHK-Cu stimulating synthesis of VEGF, FGF-2, NGF, and erythropoietin while suppressing free radicals, TGF-beta-1, TNF-alpha, and protein glycation — a profile spanning angiogenesis, nerve support, and inflammation simultaneously ^[6]. At the gene level, a Connectivity Map analysis reported GHK shifting expression of roughly 31.2% of human genes at a 50%-or-greater change threshold (approximately 59% up, 41% down), strongly stimulating ubiquitin-proteasome, DNA-repair, and antioxidant gene sets ^[2]. One correction is worth stating plainly: the widely circulated "~4,000 genes" figure is an extrapolation from a verified count of around 2,100 genes at that threshold ^[2].

At the cell level, the earliest direct evidence came from human fibroblast cultures where GHK-Cu stimulated collagen synthesis starting between 10^-12 and 10^-11 M, peaking at 10^-9 M, independent of any change in cell number — a specific metabolic effect, not a proliferative one ^[7].

What the research shows

Topical anti-aging. The 2025 review — the freshest synthesis of GHK-Cu topical efficacy — confirms that procollagen synthesis increased in 70% of GHK-Cu-treated subjects versus 50% for vitamin C and 40% for retinoic acid, and evaluates palmitoylation and microneedle pretreatment as strategies to breach the delivery barrier (about 134 nmol GHK permeated with microneedling versus none through intact skin) ^[1]. The same comparison figures appear in the canonical 2015 skin-regeneration review, which also documents improved skin laxity, clarity, fine lines, wrinkle depth and density in placebo-controlled trials ^[4].

Hair growth. In a 6-month RCT of 45 men with androgenetic alopecia, a complex of 5-aminolevulinic acid and glycyl-histidyl-lysine peptide increased hair count by 52.6 at 100 mg/mL and 71.5 at 50 mg/mL versus only 9.6 for placebo (p<0.05), with no adverse events in any group ^[3]. The compound was a combination, not pure GHK-Cu, but it is the strongest controlled human efficacy signal for a GHK-containing topical in the record.

Tissue remodeling. The foundational 2008 review established GHK-Cu's breadth across multiple repair contexts: collagen, elastin, metalloproteinase rebalancing, angiogenic factor stimulation, anti-inflammatory suppression, and chemoattraction of repair cells ^[6]. The 1988 fibroblast culture study was the original quantitative confirmation of dose-dependent collagen synthesis without altered proliferation ^[7].

Skin penetration. An ex vivo human skin-penetration study measured a copper permeability coefficient of 2.43 ± 0.51 × 10^-4 cm/h across dermatomed skin, with 136.2 ± 17.5 µg/cm² permeating over 48 hours and 97 ± 6.6 µg/cm² retained as a measurable dermal depot ^[5]. This quantifies the copper delivery achievable with standard formulations — and implicitly, the ceiling that intact-stratum-corneum barriers impose without delivery aids.

Reported effects, cautions & safety

Topical copper-tripeptide products carry a long real-world cosmetic safety record, but several cautions follow directly from the research literature:

• No approved drug indication. GHK-Cu has no FDA- or EMA-approved therapeutic use by any route. Topical copper tripeptide-1 is a legal cosmetic ingredient in the US, EU, and UK; injectable or systemic use is unapproved and research-only ^[1].
• Poor transdermal delivery. Free GHK has a calculated clogP of -2.24, meaning it permeates intact skin poorly without formulation aids. Most of the human evidence used delivery-optimized topicals or ex vivo skin ^[1][5].
• Localized hyperpigmentation. Increased local pigmentation has been reported with some copper-peptide topical applications, including approximately 40% incidence in one acne-scar microneedling study.
• Vitamin C and low-pH incompatibility. Copper(II) reduction or competition can destroy both GHK-Cu and ascorbic acid when combined — a known formulation and user-error risk.
• Theoretical copper accumulation. Repeated systemic delivery of a copper-carrying peptide raises a theoretical copper-balance concern, particularly in anyone with impaired copper clearance. No human copper-toxicity cases attributed to GHK-Cu appear in the peer-reviewed record, but there is no long-term systemic safety data either.
• Single-investigator concentration. A significant share of the foundational review and mechanistic literature originates from one investigator and collaborators, limiting independent replication of the broader gene-expression and anti-aging claims ^[2].

The research has no compiled community-anecdote reports for GHK-Cu's broader systemic use; the cautions above are drawn from the cited literature.

Where it fits in skin and aesthetics research

GHK-Cu is the senior member of this desk — the best-characterized molecule, the most peer-reviewed, and the one with real controlled human data, even if most of it lives on the skin's surface. What separates it from bolder claims made for the compound is that "best-documented" still means small trials, a delivery problem, and a literature partly anchored to one research group. Read alongside GLOW, which builds a multi-peptide combination on top of GHK-Cu's constituent record, this page illustrates why the single-molecule story matters before any stack-level inference can be taken seriously. See the comparison page for how the two line up.